Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
JNJ-56021927
Ningbo Cancer Hospital
High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.
1 trial -
Jianpi Lishi Jiedu Granules
The First People's Hospital of Lianyungang
Colorectal Adenoma
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion
Ningbo Cancer Hospital
High risk resected melanoma.
1 trial -
KHK7580
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Secondary Hyperparathyroidism
1 trial -
KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion
Ningbo Cancer Hospital
Uveal Melanoma
1 trial -
Ketorolac
The First People's Hospital of Lianyungang
Aortic Dissection
1 trial -
Keverprazan Hydrochloride tablets + high dose amoxicillin
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education
1 trial -
L-alanyl-L-glutamine dipeptide
Hospital Authority, Hong Kong
Coronary Artery Bypass
1 trial -
L-ornithine-L-aspartate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Decompensated Cirrhosis
1 trial -
LC-1000
Hospital Authority, Hong Kong
Coronary Artery Disease
1 trial -
LETROZOLE, ANASTROZOLE, CAPECITABINE, PACLITAXEL, CAPECITABINE, Verzenios 50 mg film-coated tablets, FULVESTRANT
Ningbo Cancer Hospital
Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement
1 trial -
LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN
Ningbo Cancer Hospital
Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size β₯ 50mm.
1 trial -
LETROZOLE, EXEMESTANE, ANASTROZOLE, PALBOCICLIB, FULVESTRANT
Ningbo Cancer Hospital
ER+/HER2- metastatic breast cancer
1 trial -
LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN
Ningbo Cancer Hospital
Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).
1 trial -
LOMUSTINE
Ningbo Cancer Hospital
Glioblastoma
1 trial -
Lenvatinib
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Letrozole
The First People's Hospital of Lianyungang
Polycystic Ovary Syndrome
1 trial -
Levamlodipine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Oral Contraceptive
1 trial -
Lipid-lowing Tea
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hyperlipidemia
1 trial -
Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immunoglobulin Light-chain Amyloidosis
1 trial -
Live Combined Bifidobacterium and Lactobacillus TabletsγCompound Glutamine Entersoluble capsules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation Proctitis
1 trial -
Loperamide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diarrhea-predominant Irritable Bowel Syndrome
1 trial -
Low-dose complex B-vitamins
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hyperhomocysteinemia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources